CSIMarket
 
Celldex Therapeutics inc   (NASDAQ: CLDX)
Other Ticker:  
 
 
Price: $21.5300 $-0.94 -4.183%
Day's High: $23.1 Week Perf: -7 %
Day's Low: $ 21.18 30 Day Perf: -18.85 %
Volume (M): 980 52 Wk High: $ 53.18
Volume (M$): $ 21,099 52 Wk Avg: $34.52
Open: $22.58 52 Wk Low: $21.18



 Market Capitalization (Millions $) 1,427
 Shares Outstanding (Millions) 66
 Employees 42
 Revenues (TTM) (Millions $) 10
 Net Income (TTM) (Millions $) -154
 Cash Flow (TTM) (Millions $) 15
 Capital Exp. (TTM) (Millions $) 2

Celldex Therapeutics Inc
Celldex Therapeutics Inc is a biopharmaceutical company that focuses on the development of innovative immunotherapies to treat various types of cancer and other difficult-to-treat diseases. The company's goal is to harness the power of the immune system to combat diseases by targeting specific proteins and pathways that play a role in disease progression.

Celldex Therapeutics has a diverse pipeline of product candidates, which includes novel monoclonal antibodies, antibody-drug conjugates, and vaccines. These candidates are designed to target and stimulate the immune system to recognize and destroy cancer cells, while also reducing the toxic side effects associated with traditional chemotherapy treatments.

One of the company's lead candidates is Glembatumumab Vedotin, an antibody-drug conjugate currently in clinical trials for the treatment of triple-negative breast cancer. Another promising candidate is CDX-1140, a fully human monoclonal antibody that activates the immune system's natural killer cells to fight against cancer.

Celldex Therapeutics has established collaborations with other pharmaceutical companies and research institutions to further advance their product candidates. They are committed to advancing scientific knowledge and improving patient outcomes through research and development of innovative immunotherapies.


   Company Address: Perryville III Building Hampton 8827 NJ
   Company Phone Number: 200-7500   Stock Exchange / Ticker: NASDAQ CLDX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BZYR     
NTLA   -0.42%    
AMGN   -5.87%    
BMY   -7.1%    
GILD   -4.31%    
LLY        2.45% 
• View Complete Report
   



Clinical Study

HAMPTON, N.J., Dec. 19, 2024 In a significant stride for dermatological therapeutics, Celldex Therapeuti...

Published Thu, Dec 19 2024 1:01 PM UTC

Celldex Therapeutics Advances Barzolvolimab Research with Promising Results in Atopic Dermatitis and Urticaria HAMPTON, N.J., Dec. 19, 2024 In a significant stride for dermatological therapeutics, Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced the initiation of a Phase 2 study for barzolvolimab, aimed at addressing the debilitating effects of atopic dermatitis (AD). Co...

Clinical Study

Celldex Therapeutics Initiates Phase 1 Healthy Volunteer Study of Bispecific Antibody CDX-622 for Inflammatory Diseases

Published Wed, Nov 20 2024 1:01 PM UTC

Abstract: Celldex Therapeutics, Inc. has announced the commencement of a Phase 1a clinical trial for CDX-622, a bispecific antibody aimed at addressing chronic inflammatory diseases. This study represents an important step in evaluating the therapeutic potential of targeting key immunological pathways involved in inflammation. On November 20, 2024, Celldex Therapeutics, In...

Clinical Study

Celldex Therapeutics Announces Breakthrough 52-Week Results for Barzolvolimab in Chronic Spontaneous Urticaria ...

Published Wed, Sep 25 2024 2:45 PM UTC

In a landmark presentation at the European Academy of Dermatology and Venereology (EADV) 2024 Congress, Celldex Therapeutics announced compelling results from its Phase 2 study of Barzolvolimab in patients suffering from Chronic Spontaneous Urticaria (CSU). The study results demonstrated significant therapeutic benefits, with 71% of patients receiving the 150 mg dosage every...

Clinical Study

Celldex Therapeutics Breakthrough in Mast Cell Inhibition Promising Phase 2 Results for Barzolvolimab Across Multipl...

Published Mon, Jul 29 2024 8:01 PM UTC

Exploring the Promising Efficacy of Barzolvolimab: A Potential Game-Changer in Chronic Inducible Urticaria and Prurigo Nodularis Treatment Options In a noteworthy advancement for the management of chronic skin conditions, Celldex Therapeutics, Inc. (NASDAQ: CLDX) has unveiled a series of promising topline results from its Phase 2 clinical trials investigating barzolvolimab, ...

Clinical Study

Advancements in Treating Chronic Spontaneous Urticaria EMBARQ-CSU Trials Shed New Light on Barzolvolimab

Published Tue, Jul 16 2024 12:01 PM UTC

Chronic Spontaneous Urticaria (CSU) is a debilitating and chronic skin disorder characterized by the sudden emergence of itchy hives, swelling, and other symptoms that last for six weeks or more. It affects millions of individuals worldwide, significantly impairing their quality of life. The recurrence of symptoms and limited treatment options make CSU a challenging conditio...







Celldex Therapeutics Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com